# A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

> **NCT02572687** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 85 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Non-Small Cell Lung Cancer
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT02572687
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-19
- **Primary completion:** 2018-03-27
- **Final completion:** 2021-01-13
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02572687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02572687, "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02572687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*